Question-and-Answer SessionLee HambrightSanford C. Bernstein & Co., LLC., Research Division So we're scheduled for a 40-minute fireside chat. You should all have the pigeonhole link if you want to submit questions. We've got the iPad up here. So Tom, you've been in the Chairman role here for almost 2 years now. Maybe you can just kick us off with some opening remarks on how you see the state of the business at J&J. ...

The Dividend Kings posted a very nice gain of 3.26% in August, outpacing the SPDR S&P 500 ETF Trust ( SPY ) by a cool 1.21%. September, however, is not faring as well; SPY is up 2.9% throughI have a masters degree in Analytics from Northwestern University and a bachelors degree in Accounting. I have worked in the investment arena for over 10 years starting as an analyst and working my way up to a management role. Dividend investing is a personal hobby and I look forward to sharing my thoughts with the Seeki ...

Upfront, I'm long shares of Kenvue (NYSE: KVUE ). After poking around the name a few times following its spin-off from Johnson & Johnson ( JNJ ), I bought the stock amid the first reports that the Trump Administration was seekingI've been contributing to Seeking Alpha and other investment websites since 2011, with a general (though far from rigid) focus on value over growth. I got my Series 7 and 63 back in 1999, and watched the dot-com bubble peak and then burst in real time at a small, tech-focused retail ...

Johnson & Johnson (NYSE:JNJ) FY Conference September 24, 2025 01:10 PM ET Company ParticipantsTom Cavanaugh - Company Group Chairman, North AmericaConference Call ParticipantsLee Hambright - Senior Research Analyst, U.S. Medical DevicesLee HambrightI think we'll jump in here. Thanks everybody for joining. Lee Hambrecht, US MedTech Analyst at Bernstein. We're thrilled to host Company Group Chairman, Johnson & Johnson Innovative Medicine North America, Tom Cavanaugh. Tom, thanks so much for being here.Tom Cav ...

President Donald Trump created a potentially existential crisis for Tylenol maker Kenvue Inc. with just three words about the company’s most-recognized product: “don’t take it.” Trump’s warnings about the unproven link between Tylenol use during pregnancy to autism in children risks reinvigorating a barrage of litigation over the issue that the company has sought to put behind it. A federal court in December dismissed lawsuits alleging a link between the active ingredient in the over-the-counter pain trea ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about Johnson & Johnson (JNJ) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Johnson & Johnson currently has an ...

Hi! Did you catch Jimmy Kimmel last night? The late-night host's show returned after a brief suspension over comments regarding Charlie Kirk. In case you missed it, or you're in a market where local affiliates are still refusing to air the show, we've got a rundown of all the highlights. Kimmel teared up, explaining that he never intended to make light of Kirk's death. And he called political efforts to sway networks and affiliates from airing the show "un-American," noting it wasn't just about comedy.Late ...

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! AI is eating the world—and the machines behind it are ravenous. Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink. Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and b ...

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Johnson & Johnson is one of them. Johnson & Johnson (NYSE:JNJ), a global healthcare leader, continues to strengthen its pharmaceuticals and immunology portfolio while delivering strong stock performance in 2025. This month, the company received FDA approval for a subcutaneous induction regimen of Tremfya (guselkumab) to treat adults with ulcerative colitis. As the first and only IL-23 inhibitor with a ...

Tylenol once survived a poisoning scandal. Now it has to survive President Donald Trump. Kenvue, the company behind the household brand, at least has a playbook to turn to for guidance. That's because Tylenol's original owner, Johnson & Johnson, developed it decades ago after seven people in the Chicago area died from taking its capsules because someone had laced them with potassium cyanide. The 1982 unsolved mystery became known as the "Tylenol murders."J&J's handling of the incident not only saved the br ...